Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis.
High
Whitney A
WA
Ayers
Reed A
RA
Cowper
Shawn E
SE
D001707:Biopsy, Needle; D003287:Contrast Media / Q000009:adverse effects; D005260:Female; D005355:Fibrosis / Q000209:etiology* / Q000473:pathology; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000175:diagnosis; D008297:Male; D013058:Mass Spectrometry; D018570:Risk Assessment; D012494:Sampling Studies; D012680:Sensitivity and Specificity; D012867:Skin / Q000187:drug effects
D003287:Contrast Media; D019786:Gadolinium DTPA